Details for Patent: 9,828,361

« Back to Dashboard

Which drugs does patent 9,828,361 protect, and when does it expire?

Patent 9,828,361 protects ZENBEXUS and is included in one NDA.

This patent has eighty-two patent family members in thirty-two countries.

Summary for Patent: 9,828,361

Title:	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
Abstract:	Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Inventor(s):	Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
Assignee:	Celgene Corp
Application Number:	US15/040,971
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,828,361

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	9,828,361		Y	Y
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	9,828,361		Y	Y

International Family Members for US Patent 9,828,361

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	081058
Australia	2011215877
Canada	2787823
China	102822165